BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ZS Pharma Announces Positive Top-Line Results of Phase 3 Trial of ZS-9 in Patients With Hyperkalemia


11/10/2013 12:33:13 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

COPPELL, Texas--(BUSINESS WIRE)--ZS Pharma, a specialty pharmaceutical company developing novel treatments for kidney, cardiovascular and liver disorders, today announced top-line results from the Acute Phase of its pivotal Phase 3 ZS-003 trial of ZS-9, a novel, investigational treatment for hyperkalemia. Preliminary top-line analyses of the safety and efficacy results of the Acute Phase showed that the trial met its primary endpoint, demonstrating a rapid, statistically significant reduction in serum potassium (K+) over the initial 48 hours. These results confirm the positive results demonstrated in the Phase 2 trial (ZS-002), a multicenter, double-blind, placebo-controlled study, which also met its primary efficacy endpoint. The results of both of these clinical trials support the safety and efficacy of ZS-9 in treating hyperkalemia, regardless of underlying cause. The data were presented by Stephen R. Ash, M.D., of Indiana University Health Arnett, during the High-Impact Clinical Trials Oral Session at ASN’s Kidney Week 2013.

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

ZS Pharma
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES